ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent. ReCognitION is an acronym for Recognition and Validation of Druggable Targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. The project is built on the successful OPTIMISTIC clinical trial. The OPTIMISTIC trial showed a positive effect of lifestyle interventions on the social participation and physical activity of Myotonic Dystrophy patients. In ReCognitION, Radboudumc will work with partners in Gent, Paris, Prague and Ottawa to understand the molecular pathways underlying the response to cognitive behavioural therapy and to identify drugs targeting these pathways that may consolidate or reinforce the effect of cognitive behavioural therapy.
ReCognitION was funded by ZON-MW and similar national funding organisations in Belgium, France, the Czech Republic and Canada under the eRARE program.
Related news items
Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path16 September 2021
The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.read more
Infections increase risk to develop dementia16 September 2021
In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.read more
ENABLECARES launches a course on entrepreneurship for PhD candidates and postdocs15 September 2021
Are you thinking about what to do after your PhD? Want to know more about entrepreneurship? This course gives you insight in many aspects of entrepreneurship and research in industry.read more